Novavax Reports Fourth Quarter and Year-End 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq end lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Novavax (NVAX) Weakness Over Increased Spending is Unwarranted - FBR
March 1, 2016 7:22 AM ESTFBR Capital analyst, Vernon Bernardino, reiterated his Outperform rating as vaccine developer Novavax (NASDAQ: NVAX) reported 4Q15 financial results and presented highlights of its 2015 accomplishments: completion of enrollment ahead of guidance for the RSV vaccine Phase III study in elderly adults, completion of enrollment in the Phase II rollover study, and initiation of a second RSV vaccine Phase III study (maternal immunization of infants). The analyst believes... More
Novavax (NVAX) Misses Q4 EPS by 15c
February 29, 2016 7:33 AM ESTNovavax (NASDAQ: NVAX) reported Q4 EPS of ($0.29), $0.15 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $5.9 million versus the consensus estimate of $8.07 million.
2016 Anticipated Events:
Announce top-line data from Resolve, the... More